News & Updates

Evidence on the association of weak opioids with a higher risk of oesophageal and colorectal cancer is not reliable, but there appears to be a small association with gastric cancer, suggests a study.

Novel systemic treatments are similarly effective in reducing the risk of progression or death in patients with metastatic hormone-sensitive (mHSPC) and castration-resistant prostate cancer (mCRPC), irrespective of visceral metastasis status, reports a study.

Prostate cancer treatment upends sexual function in men, but the good news is that supervised resistance and aerobic workout can counter these sexual side effects, according to a study presented at ASCO Breakthrough 2023.

A dexamethasone-free regimen helps improve control of nausea and vomiting in patients receiving “highly emetogenic” chemotherapy, with the antiemetic effect being superior to that of a dexamethasone-based regimen, according to the results of a phase III trial presented at ASCO Breakthrough 2023.

In the treatment of refractory metastatic colorectal cancer (mCRC), the addition of bevacizumab to trifluridine/tipiracil (FTD/TPI) does not appear to hurt the quality of life (QoL), with patients receiving add-on bevacizumab being able to maintain their QoL for a longer period than those receiving FTD/TPI monotherapy, according to a post hoc analysis of the phase III SUNLIGHT trial.

At a first screening colonoscopy, older patients are more likely to have a detection of adenomatous polyps and colorectal cancer (CRC), reveals a study.